PepGen shares are trading lower after the company reported Q4 financial results. The FDA placed a partial hold on the company's FREEDOM2-DM1 Phase 2 multiple ascending dose, randomized, placebo-controlled clinical trial of PGN-EDODM1 in patients with myotonic dystrophy type 1.